MC1R-targeted Alpha-particle Monotherapy and Combination Therapy Trial With Nivolumab in Adults With Advanced Melanoma

In this first-in human, phase I/IIa study, the safety and efficacy of \[212Pb\]VMT01, an alpha-particle emitting therapeutic agent targeted to melanocortin sub-type 1 receptor (MC1R) is being evaluated as a monotherapy and in combination with nivolumab in subjects with unresectable and metastatic melanoma.

Trial Details

NCT ID

NCT05655312

Phase

PHASE1 / PHASE2

Sponsor

Perspective Therapeutics

Status

RECRUITING

Cancer Type

Melanoma

Interventions

[203Pb]VMT01
[212Pb]VMT01
Nivolumab

Locations (sample)

Orange, California, United States|33.78779,-117.85311
Jacksonville, Florida, United States|30.33218,-81.65565
Miami, Florida, United States|25.77427,-80.19366
Sarasota, Florida, United States|27.33643,-82.53065
Iowa City, Iowa, United States|41.66113,-91.53017

Key Eligibility Criteria

Ability to understand and willingness to provide informed consent, willingness to comply with all study procedures for the duration of the study
Aged ≥ 18 years
Diagnosed with unresectable Stage III or Stage IV metastatic or recurrent melanoma
Previously progressed (radiological progression) on at least one approved systemic therapy for advanced melanoma

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Melanoma Trials on Trialify →